BridgeBio Pharma Inc’s recent filing unveils that its President and CFO Trimarchi Thomas unloaded Company’s shares for reported $2.09 million on Aug 21 ’25. In the deal valued at $49.48 per share,42,237 shares were sold. As a result of this transaction, Trimarchi Thomas now holds 421,081 shares worth roughly $20.67 million.
Then, Kumar Neil sold 26,156 shares, generating $1,276,927 in total proceeds. Upon selling the shares at $48.82, the Chief Executive Officer now owns 223,090 shares.
Before that, THOMAS TRIMARCHI bought 42,237 shares. BridgeBio Pharma Inc shares valued at $2,090,077 were divested by the Officer at a price of $49.48 per share.
A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Jefferies began covering BBIO with “Buy” recommendation on July 14, 2025. Oppenheimer revised its rating on July 09, 2025. It rated BBIO as “an Outperform” which previously was an “a Perform”.
Price Performance Review of BBIO
On Friday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock fall -2.29% to $49.08. Over the last five days, the stock has lost -4.36%. BridgeBio Pharma Inc shares have risen nearly 91.27% since the year began. Nevertheless, the stocks have risen 78.86% over the past one year. While a 52-week high of $51.86 was reached on 08/14/25, a 52-week low of $21.72 was recorded on 01/02/25.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 48.37, which if violated will result in even more drops to 47.66. On the upside, there is a resistance level at 50.26. A further resistance level may holdings at 51.44.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-07-31, dropping by -3.32 million shares to a total of 18.52 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 21.83 million shares. There was a decline of -17.9%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 17, 2025 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $49 price target.
